Biotechnology The UK subsidiary of US biotech firm Seagen today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens. 22 February 2021